Expanded therapeutic use for melanoma antibody

The monoclonal antibody ipilimumab, indicated for the treatment of adults with advanced melanoma, is now licensed for first-line use

The monoclonal antibody ipilimumab (Yervoy), indicated for the treatment of adults with advanced (unresectable or metastatic) melanoma, is now licensed for first-line use.1

Ipilimumab enhances T-cell mediated responses by blocking the inhibitory signal of cytotoxic T-lymphocyte antigen-4 (CTLA-4). This results in T-cell activation, proliferation and lymphocyte infiltration into tumours, leading to tumour cell death.1

Analysis of pooled data for ipilimumab from phase II and III trials in chemotherapy-naive patients (n=78) showed estimated one- and two-year survival rates of 54.1% (95% CI 42.5-65.6) and 32% (95% CI 20.7-42.9), respectively.

In two retrospective observational studies in treatment-naive patients receiving ipilimumab (n=120 and n=61), estimated
one-year survival rates were 59.5% (95% CI 50.1-67.8) and 49.3% (95% CI 35.6-61.6).1


1. Yervoy Summary of Product Characteristics, December 2013.

Read these next

New treatment for patients with advanced melanoma

New treatment for patients with advanced melanoma

Dabrafenib (Tafinlar) is a new treatment option for...

Survival rates in melanoma

Survival rates in melanoma

Subsequent melanomas in patients with multiple primary...

Clinical Review: Malignant melanoma

Clinical Review: Malignant melanoma

Early diagnosis of malignant melanoma is crucial because...

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.